_-8>,0W2B0SL#<+V?17~
SYSTEM PROCESSING...
_-8>,0W2B0SL#<+V?17~
SYSTEM PROCESSING...
Posted: 2025-04-13 18:57:16 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-13 18:57:46 UTC
Verified By
Rollup News
Second-generation antipsychotics (SGAs) can significantly increase the risk of cardiovascular disease and type 2 diabetes, leading to a reduced life expectancy in people with psychotic disorders. The text explores the pathophysiology and clinical strategies for managing metabolic dysfunction associated with SGA use, emphasizing the importance of monitoring, lifestyle interventions, and antipsychotic selection.
SGAs increase the risk of cardiovascular disease and type 2 diabetes.
Metabolic syndrome is prevalent in patients with schizophrenia on SGAs.
SGAs disrupt appetite regulation, leading to hyperphagia and fat accumulation.
Lifestyle interventions and routine monitoring can improve outcomes.
Antipsychotic selection and pharmacological options can mitigate metabolic risks.
Weight gain exceeding 7% of baseline with certain antipsychotics.
Glucose and lipid dysregulation independent of weight gain.
High prevalence of metabolic syndrome in patients with schizophrenia.
Disruption of appetite regulation leading to overeating.
Reduced adherence due to weight gain and metabolic effects.